Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT01062451
Other study ID # H-23235
Secondary ID R01DA023468DPMC
Status Completed
Phase Phase 1
First received
Last updated
Start date May 2009
Est. completion date November 20, 2013

Study information

Verified date April 2022
Source Baylor College of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The primary objective is to determine the dose dependent effects of treatment with perindopril on methamphetamine (MA)-induced craving and on the reinforcing effects of MA indexed by MA self-administration. We will also determine the effects of treatment with candesartan on MA-induced craving and on the reinforcing effects of MA indexed by MA self-administration.


Description:

Our preliminary data indicate that the ACE inhibitor perindopril can attenuate MA-induced drug craving, suggesting that perindopril should be evaluated as a treatment for MA dependence. Candesartan works similarly to perindopril but should lack the U-shaped dose response. Like perindopril, candesartan is used for hypertension. Whereas perindopril reduces the synthesis of angiotensin II, candesartan blocks angiotensin II receptors.


Other known NCT identifiers
  • NCT00249665

Recruitment information / eligibility

Status Completed
Enrollment 80
Est. completion date November 20, 2013
Est. primary completion date November 20, 2013
Accepts healthy volunteers No
Gender All
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria: - Be English-speaking non-treatment-seeking volunteers. - Be between 18-55 years of age. - Meet DSM-IV TR criteria for MA dependence. - Have a self-reported history of using MA by the IV route. - Have vital signs as follows: resting pulse between 50 and 90 bpm, blood pressures between 85-150mm Hg systolic and 45-90mm Hg diastolic. - Have a breathalyzer test indicating an undetectable blood alcohol level upon admission. - Have hematology and chemistry laboratory tests that are within normal (+/- 10%) limits with the following exceptions: a) liver function tests (total bilirubin, ALT, AST, and alkaline phosphatase) < 3 x the upper limit of normal, and b) kidney function tests (creatinine and BUN) < 2 x the upper limit of normal. - Have a baseline ECG that demonstrates normal sinus rhythm, normal conduction, and no clinically significant arrhythmias. - Have a medical history and brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the admitting physician and the principal investigator. Adult ADHD is allowable, as long as symptoms do not interfere with participation. - Demonstrate MA-induced craving, evidenced by a change in "desire" greater than 20 on a 0 to 100mm VAS. - Weigh between 60 and 100kg. Exclusion Criteria: - Have any previous medically adverse reaction to MA, including loss of consciousness, chest pain, or epileptic seizure. - Have neurological or psychiatric disorders, such as: episode of major depression within the past 2 years as assessed by MINI; lifetime history of schizophrenia, other psychotic illness, or bipolar illness as assessed by MINI; current organic brain disease or dementia assessed by clinical interview; history of or any current psychiatric disorder which would require ongoing treatment or which would make study compliance difficult; history of suicide attempts within the past three months and/or current suicidal ideation/plan; history of psychosis occurring in the absence of current MA use. - Meet DSM-IV criteria for abuse or dependence on alcohol or other drugs, except for nicotine or marijuana. - Have evidence of clinically significant heart disease or hypertension, as determined by the PI. - Have evidence of untreated or unstable medical illness including: neuroendocrine, autoimmune, renal, hepatic, or active infectious disease. - Have HIV and are currently symptomatic, have a diagnosis of AIDS, or are receiving antiretroviral medication. - Be pregnant or nursing. Other females must either be unable to conceive (i.e., surgically sterilized, sterile, or post-menopausal) or be using a reliable form of contraception (e.g., abstinence, birth control pills, intrauterine device, condoms, or spermicide). All females must provide negative pregnancy urine tests before study entry, and weekly throughout the study. - Have any history of asthma, chronic coughing and wheezing, or other chronic respiratory illnesses. - Currently use alpha or beta agonists, theophylline, or other sympathomimetics. - Have any other illness, condition, or use of medications, which in the opinion of the P.I. and/or the admitting physician would preclude safe and/or successful completion of the study. Rationale for Other Exclusion Criteria: Participants with asthma or who take medications for asthma are excluded due to potential adverse interactions between treatment medications and MA. Participants who use alcohol heavily are excluded due to the potential of withdrawal symptoms in the hospital. Participants with active HIV disease are excluded to avoid potentially exacerbating their underlying illness and because of potential drug interactions. Reliable methods of birth are required to prevent pregnancy, and the use of frequent urine pregnancy tests will exclude women who become pregnant. This is important because perindopril can produce significant birth defects. Criteria for Discontinuation Following Initiation: Participants will be discharged if they have a positive breath test indicating use of alcohol or a urine test indicating use of illicit use of drugs while on the study, if they do not comply with study procedures, or if they do not tolerate MA.

Study Design


Intervention

Drug:
Perindopril
8 mg taken orally from days 0 through 7.
Placebo
Placebo treatment daily.
Candesartan
16 mg taken orally from days 0 through 7.

Locations

Country Name City State
United States Michael E. DeBakey VA Medical Center Houston Texas

Sponsors (2)

Lead Sponsor Collaborator
Baylor College of Medicine National Institute on Drug Abuse (NIDA)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary The dose-dependent effects of an ace inhibitor or an angiotensin receptor blocker on MA- and cue-induced craving and on the reinforcing effects of MA indexed by MA self-administration. Participants demonstrating MA-induced craving will then be randomized to active study medication (perindopril or candesartan) or matched placebo (day 0). Over days 4 to 7 a variety of procedures will be completed to assess effects of MA and cue-induced craving. On day 7, reinforcing effects will be assessed will be assessed using self-administration procedures. 7 days
Secondary The effects of an ace inhibitor or an angiotensin receptor blocker on subjective measures. On days 3 and 5, participants will receive sample doses of 15mg or 30mg MA paired with a dose of placebo saline separated by 180 min, with the order of administration randomized. Subjective effects of MA will be assessed using visual analogue scales (VAS). 7 days
See also
  Status Clinical Trial Phase
Active, not recruiting NCT04070521 - EEG Monitoring in the Emergency Department
Completed NCT00729391 - Women-Focused HIV Prevention in the Western Cape Phase 2/Phase 3
Active, not recruiting NCT03129334 - Preventing Prescription Drug Abuse in Middle School Students N/A
Completed NCT02733003 - Implementation Research for Vulnerable Women in South Africa N/A
Completed NCT02573948 - Feasibility of Interventions on People Who Inject Drugs in Vietnam
Completed NCT02282306 - Phone Interview to Prevent Recurring Opioid Overdoses N/A
Withdrawn NCT01847300 - cSBI-M for Young Military Personnel N/A
Withdrawn NCT01523444 - Advancing Adolescent Screening and Brief Intervention Protocols in Primary Care Settings Phase 3
Completed NCT01481428 - Reducing High Risk Behavior in Treatment Court Phase 1
Completed NCT01591239 - Home-Based Program to Help Parents of Drug Abusing Adolescents N/A
Completed NCT01601743 - Exercise as a Behavioral Treatment for Cocaine Dependence N/A
Active, not recruiting NCT00847548 - Treatment of Intimate Partner Violence and Substance Abuse in a Forensic Setting N/A
Completed NCT01614015 - Building Outcomes With Observation-Based Supervision: An FFT Effectiveness Trial Phase 2
Withdrawn NCT01228890 - Primary Care Internet-Based Depression Prevention for Adolescents (CATCH-IT) Phase 3
Completed NCT01621334 - The Men's Domestic Abuse Check-Up Engages Adult Men Concerned About Their Abusive Behavior and Alcohol or Drug Use Phase 1
Completed NCT00841711 - Transitions: Linkages From Jail To Community N/A
Completed NCT00717444 - Healthy Activities for Prize Incentives N/A
Completed NCT00685074 - Computer-based Brief Intervention for Perinatal Substance Abuse Phase 1/Phase 2
Completed NCT01188434 - Integrating Interventions for Maternal Substance Abuse Phase 1
Completed NCT01465490 - Monitoring and Feedback in Substance Abuse Treatment Phase 1/Phase 2